Top Markets
Coin of the day
Crossject Société Anonyme Crossject Société Anonyme

Crossject Société Anonyme

ALCJ
株式のランク #12697
Crossject Société Anonyme develops needle-free injection systems. The company... Crossject Société Anonyme develops needle-free injection systems. The company develops ZENEO, a needle-free, prefilled, and single-use auto-injector. Its clinical stage drugs comprise Sumatriptan, which is used for of treatment migraines and cluster headaches; Adrenaline for treating anaphylactic shock; Hydrocortisone that is used for treatment of acute adrenal crisis; Midazolam for treating epileptic seizure; Naloxone used for treatment of overdose; Apomorphine, for treating temporary paralysis in parkinson's disease; Methotrexate used for treatment of rheumatoid arthritis; and Terbutaline, for treating severe asthma crisis. The company was founded in 1997 and is based in Dijon, France.
株価
$2.04
時価総額
$122.58M
変化(1日)
4.48%
変化(1年)
-1.05%
FR
取引 Crossject Société Anonyme (ALCJ)

カテゴリー

Crossject Société Anonyme(ALCJ)の収益
Dec 2025 時点の収益 TTM: $1.74M
Crossject Société Anonyme の最新の財務報告によると、現在の収益 (TTM) は $1.74M です。2023 年には $160.29K の収益があり、これは 2022 年の $1.02M と比較して 減少 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Crossject Société Anonyme の収益履歴(2010 ~ 2026)
各年末の収益
収益 変化
2026 (TTM) $1.74M -59.37%
2024 $4.28M 2,571.33%
2023 $160.29K -84.34%
2022 $1.02M -1.33%
2021 $1.04M -82.42%
2020 $5.90M 951.59%
2019 $561.00K -80.03%
2018 $2.81M -27.63%
2017 $3.88M 159.26%
2016 $1.50M -13.08%
2015 $1.72M 2.76%
2014 $1.68M 30.22%
2013 $1.29M 176.01%
2012 $466.30K -44.58%
2011 $841.44K 214.68%
2010 $267.40K 0.00%
同業他社の収益
企業 収益 収益の差
$10.58B 608,081.77%
US
$33.43B 1,921,073.30%
FR
$4.22B 242,477.69%
DE
$6.27B 360,357.63%
JP
$21.37B 1,227,804.05%
US